Impact of empirical oseltamivir discontinuation in hospitalized patients with community-acquired pneumonia after confirmed negative for influenza

Article Figures & Data

Table 1

- Baseline characteristics.

Factor	Empirical oseltamivir discontinuation
Factor	Appropriate (n=66)	Late (n=144)	Total (n=210)
Percentage of diabetes diagnosis	45.45%	46.53%	46.19%
Percentage of hypertension diagnosis	51.52%	54.86%	53.81%
Percentage of chronic kidney diseases	19.70%	7.64%	11.43%
Percentage of liver disease diagnosis	6.06%	7.69%	7.18%
Percentage of pulmonary disease diagnosis	34.85%	29.86%	31.43%
Percentage of cardiovascular diagnosis	45.45%	34.72%	38.10%
Percentage of cancer diagnosis	10.61%	8.33%	9.05%
Average baseline creatinine clearance	65.08	72.87	70.41
Average length of stay	11.44	11.59	11.54

Table 2

- Associated infection during hospital stay.

Factor	Empirical oseltamivir discontinuation
Factor	Appropriate (n=66)	Late (n=144)	Total (n=210)
Percentage of concurrent viral infection*	1.52%	6.25%	4.76%
Percentage of bacterial infection	36.36%	29.86%	31.90%
Percentage of bacterial specimens from blood	13.64%	5.56%	8.10%
Percentage of bacterial specimens from sputum	15.15%	15.97%	15.71%
Percentage of bacterial specimens from urine	9.09%	9.72%	9.52%
Percentage of bacterial specimens from cerebral	0.00%	0.69%	0.48%

↵*viruses include Coronavirus, Adenovirus, Human metapseumovirus, Rhinovirus, and Parainfleunza

Table 3

- Frequency of modifying factors.

Factor	Empirical oseltamivir discontinuation
Factor	Appropriate (n=66)	Late (n=144)	Total (n=210)	P-value
Age
>65	34 (32.1)	72 (67.9)	106	0.96
≥65	32 (30.8)	72 (69.2)	104	0.96
Gender
Male	30 (29.4)	72 (70.6)	104	0.64
Female	36 (33.3)	72 (66.7)	108	0.64
Body mass index
Underweight	3 (42.9)	4 (57.1)	7	0.17
Normal	15 (23.1)	50 (76.9)	65
Overweight & obese	48 (34.7)	90 (65.2)	138
Admission year
2016-2017	38 (31.4)	83 (68.6)	121	0.99
2018-2019	28 (31.4)	61 (68.5)	89	0.99

Table 4

- Frequency of perception variables.

Factor	Empirical oseltamivir discontinuation
Factor	Appropriate (n=66)	Late (n=144)	Total (n=210)	P-value
ICU patients
Non-ICU	44 (26.1)	124 (73.8)	168	0.02
ICU	22 (52.3)	20 (47.6)	42
Concurrent antibiotic use
No	5 (38.4)	8 (61.5)	13	0.55
Yes	16 (30.9)	163 (69.0)	197
Charlson comorbidity index^*
Average score	2.88	2.5	2.61	0.23

Table 5

- Logistic regression model predicting empirical oseltamivir discontinuation.

Odds ratio estimates	Demographics and perception
Odds ratio estimates	Odds ratio	95% CI
Age
>65	1.145	0.59 - 2.22
≥65	1.145	0.59 - 2.22
Gender
Male	0.81	0.43 - 1.53
Female	0.81	0.43 - 1.53
Body mass index
Underweight	2.23	0.40 - 13.1
Overweight and obese	1.89	0.90 - 3.97
Normal	1.89	0.90 - 3.97
Admission year
2016-2017	0.88	0.46 - 1.68
2018-2019	0.88	0.46 - 1.68
ICU patients*
Yes	0.30	0.14 - 0.64
No	0.30	0.14 - 0.64
Antibiotic use
No	1.29	0.34 - 4.94
Yes	1.29	0.34 - 4.94
Charlson comorbidity	1.16	0.96 - 1.42

Table 6

- Predicting readmission rate and length of stay by continued empirical oseltamivir treatment

Predictor	30-day readmission	60-day readmission	90-day readmission	Length of stay
Predictor	Estimate (95% CI)	Estimate (95% CI)	Estimate (95% CI)	Estimate* (p value)
Empirical Oseltamivir Discontinuation	0.67 (0.28 –1.59)	1.14 (0.47 – 2.78)	1.35 (0.35 – 5.27)	0.75 (0.46)